Phrontline Biopharma is dedicated to develop novel formats of ADCs for unmet medical needs in oncology. Our company specializes in selecting and optimizing dual targeting in ADC. To improve drug resistance, Phrontline has developed dual linker payload platforms to extend drug response based on several decades of clinical experience of combo chemotherapy. Convicted to improve patient’s health and guided by Science, Phrontline is dedicated to being a premier international biopharma specialized in ADC drug development.